Up next

Autoplay

Dr. Ferrari on LBH589 and Bicalutamide in CRPC

0 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Anna C. Ferrari, MD, professor, co-director, GU Research Program,
Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer (CRPC).

Show more
0 Comments sort Sort By

Up next

Autoplay